Bristol Myers Squibb Q3 2026 Results: Growth Portfolio Now 59% of Sales as Eliquis Cliff Nears
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as the Growth Portfolio hits 59% of sales. The Eliquis cliff explained.
Get the latest industry insights and trends in the pharmaceutical sector with Med Pharma News. Stay informed about groundbreaking research, regulatory updates, and market analysis.
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as the Growth Portfolio hits 59% of sales. The Eliquis cliff explained.
The Fortis Healthcare acquisition of Suguna Hospital: price per bed, the cluster strategy and the profit data not yet disclosed.
The Laurus Labs Q2 results show strong operating leverage from CDMO mix. Segment split, margin bridge and what is undisclosed.
A financial reading of the Eli Lilly Q3 2026 results: price versus volume, one-time items, the EPS cut and what guidance implies for Q4.
What the Molecular Partners workforce reduction 2026 means for cash, costs and the radiotherapy pipeline, and what is still unreported.
What the Geron IMpactMF trial discontinued means for strategy, Rytelo and the Q3 results due on 4 November 2026.
What the Nucelion Pandorum partnership means for India’s CDMO sector, PRIP-backed research and investigational eye therapies.
What the India cancer medicine price revision 2026 means for drugmakers, distributors and hospitals, with examples, criticisms and open questions.
What the Indira IVF Sabine acquisition could mean for investors: reported terms, implied valuation, IPO context and what remains undisclosed.